Artiva Biotherapeutics, Inc.
A clinical-stage biotechnology company in San Diego making off-the-shelf natural killer (NK) cell therapies, its lead candidate AlloNK designed to help antibodies destroy B-cells that drive autoimmune diseases like rheumatoid arthritis and lupus. Founded in 2019 as a spin-out of South Korea's GC Cell, it can produce thousands of doses from a single umbilical cord blood donor—a ready-made therapy that doesn't wait for a patient's own cells.
Bought 8.10M
Bought 1.43M
Sold 27.1K
Sold 8.8K
Sold 7.0K
Granted 220.0K
Sold 3.1K
Sold 7.0K
Granted 77.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Kolchinsky Peter +5 co-filersDirector, 10% owner, Director · 9 transactions | — | 34.72M | — | 8.10M | — |
| GC Cell Corp +1 co-filer10% owner · 2 transactions | +289.2% | 6.00M | — | 1.43M | — |
| Aslan FredChief Executive Officer, Director · 1 transaction | -2.6% | 1.54M | — | — | 27.1K |
| Bush JenniferCOO, CLO, Compliance Officer · 1 transaction | -2.5% | 337.9K | — | — | 8.8K |
| Horan ChristopherChief Tech Operations Officer · 1 transaction | -3% | 293.4K | — | — | 7.0K |
| Huston Thad AllenChief Financial Officer · 1 transaction | — | 220.0K | 220.0K | — | — |
| Raymon HeatherSVP, Research and Development · 1 transaction | -2% | 148.2K | — | — | 3.1K |
| Banerjee SubhashisChief Medical Officer · 1 transaction | -4.6% | 145.0K | — | — | 7.0K |
| Miralles Gines DiegoPresident & Head of R&D · 1 transaction | — | 77.5K | 77.5K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 6 months: +9.48M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.